Around 50 pharmaceutical companies are reported to have launched objections to the prices allocated to their products in the new drug price bulletin published by the Greek government on September 6.
The new list includes price cuts averaging 20% on products which account for 97% of the Greek national drugs bill. According to the Ministry of Economy, Competitiveness and Shipping, each of the 50 or so companies have opposed the new prices of no more than five of their drugs; however, GlaxoSmithKline has said that it is challenging the price cuts imposed on around 30% of its products.
Industry spokesmen are concerned at the implications of the Greek cuts for pricing throughout the rest of Europe, given that a number of other European Union (EU) nations use Greece as a reference market in their price-setting.
2 comments:
Reimbursement and prices are always hot topics. And yes, it's common that during price negotiations prices form other EU countries (usually the lowest prices) are taken into account.
From your post:
...Industry spokesmen are concerned at the implications of the Greek cuts for pricing throughout the rest of Europe, given that a number of other European Union (EU) nations use Greece as a reference market in their price-setting...
That's not quite right:
Industry spokesmen are concerned at the implications of the Greek cuts for pricing throughout the rest of Europe, given that a number of other European Union (EU) nations are just as insolvent as Greece.
FTFY.
Post a Comment